Medicare Cost-Effectiveness Changes Could Close Cost Gaps In Health Reform Bills, CBO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
CBO statements address Senate HELP committee legislation, and a preliminary analysis of the House Tri-committee bill.
You may also be interested in...
Medicaid Expansion Cost, Potential For Public Plan Savings Addressed By CBO At HELP Hearing
Expanding Medicaid eligibility could cost $500 billion over 10 years, according to a new Congressional Budget Office estimate. CBO also suggests a public plan would not reduce health care costs or increase insurance coverage among the uninsured.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.